Seismic Therapeutic, a machine learning immunology company, has appointed Julie Eastland as an Independent Director to its Board. Ms. Eastland brings over 30 years of experience in finance and strategy within clinical stage biotechnology companies. Her expertise spans the drug development process, from discovery to commercialization, particularly in oncology and immunology.
Ms. Eastland most recently served as CEO and Board Director of Harpoon Therapeutics (HARP), which was acquired by Merck & Co in March 2024. She has held various C-level executive roles in both private and public companies, including ReCode Therapeutics, Rainier Therapeutics, and Cascadian Therapeutics. Her experience includes guiding biotechnology companies through significant organizational growth and navigating financial and operational challenges.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.